复星医药子公司聚乙二醇3350电解质散获国家药监局批准上市

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

## 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People’s Republic of China with limited liability)

(Stock Code: 02196)

### OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the “Announcement in Relation to the Approval for Drug Registration of a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “Company”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Chen Yuqing

Chairman

Shanghai, the PRC 3 August 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* for identification purposes only

Stock code: 600196 Stock abbreviation: Fosun Pharma No: Lin 2026-103

# Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Approval for Drug Registration of a Subsidiary

|The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.<br><br>|
|---|


I. Overview

Recently, the drug registration application for Polyethylene Glycol (3350) and Electrolytes Powder (the “Drug”) of Suzhou Erye Pharmaceutical Co., Ltd. * (蘇州二葉 製藥有限公司), being a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the “Company”), has been approved by the National Medical Products Administration. The approved indication is (1) for the treatment of chronic constipation in children 1 to 11 years of age; (2)for the treatment of faecal impacion in children from the age of 5 years, defined as refractory constipation with faecal loading of the rectum and/or colon.

II. Registration Information of the Drug Generic Name: Polyethylene Glycol (3350) and Electrolytes Powder Dosage Form: Powder Strength: 6.9g per bag Registered Category: Chemicals Category 3 Marketing Authorization Holder: Suzhou Erye Pharmaceutical Co., Ltd. * (蘇州二葉

製藥有限公司) Drug Approval Number: Guo Yao Zhun Zi H20265407

III. Research and Development of the Drug and Marketing Situation of Similar Drugs

As of June 2026, the Group (i.e., the Company and its subsidiaries/units, the same hereinafter) has invested approximately RMB2.62 million (unaudited) in total in the research and development of the Drug at current stage.

According to the latest data from IQVIA CHPA1, in 2025, the sales of Polyethylene Glycol Electrolytes Powder in China (excluding Hong Kong, Macao, and Taiwan regions) were approximately RMB598 million.

IV. Impact on the Listed Company and Risk Warning This approval for marketing of the Drug will further enrich the product line of the

Group.

Due to the industry characteristics of pharmaceutical products, the specific sales performance after the market launch of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 3 August 2026

* For identification purposes only

1 provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data represents the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.